These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Diminished CD4+/CD25+ T cell and increased IFN-gamma levels occur in dogs vaccinated with Leishmune in an endemic area for visceral leishmaniasis. de Lima VM; Ikeda FA; Rossi CN; Feitosa MM; Vasconcelos RO; Nunes CM; Goto H Vet Immunol Immunopathol; 2010 Jun; 135(3-4):296-302. PubMed ID: 20132994 [TBL] [Abstract][Full Text] [Related]
7. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonçalo do Amarante, RN). Borja-Cabrera GP; Correia Pontes NN; da Silva VO; Paraguai de Souza E; Santos WR; Gomes EM; Luz KG; Palatnik M; Palatnik de Sousa CB Vaccine; 2002 Sep; 20(27-28):3277-84. PubMed ID: 12213397 [TBL] [Abstract][Full Text] [Related]
8. Comparison of two commercial vaccines against visceral leishmaniasis in dogs from endemic areas: IgG, and subclasses, parasitism, and parasite transmission by xenodiagnosis. Fernandes CB; Junior JT; de Jesus C; Souza BM; Larangeira DF; Fraga DB; Tavares Veras PS; Barrouin-Melo SM Vaccine; 2014 Mar; 32(11):1287-95. PubMed ID: 24406392 [TBL] [Abstract][Full Text] [Related]
9. Decrease of the incidence of human and canine visceral leishmaniasis after dog vaccination with Leishmune in Brazilian endemic areas. Palatnik-de-Sousa CB; Silva-Antunes I; Morgado Ade A; Menz I; Palatnik M; Lavor C Vaccine; 2009 Jun; 27(27):3505-12. PubMed ID: 19464528 [TBL] [Abstract][Full Text] [Related]
10. Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune vaccine. Santos FN; Borja-Cabrera GP; Miyashiro LM; Grechi J; Reis AB; Moreira MA; Martins Filho OA; Luvizotto MC; Menz I; Pessôa LM; Gonçalves PR; Palatnik M; Palatnik-de-Sousa CB Vaccine; 2007 Aug; 25(33):6176-90. PubMed ID: 17630055 [TBL] [Abstract][Full Text] [Related]
11. Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine. Borja-Cabrera GP; Cruz Mendes A; Paraguai de Souza E; Hashimoto Okada LY; de A Trivellato FA; Kawasaki JK; Costa AC; Reis AB; Genaro O; Batista LM; Palatnik M; Palatnik-de-Sousa CB Vaccine; 2004 Jun; 22(17-18):2234-43. PubMed ID: 15149782 [TBL] [Abstract][Full Text] [Related]
13. Canine Leishmania vaccines: still a long way to go. Gradoni L Vet Parasitol; 2015 Feb; 208(1-2):94-100. PubMed ID: 25620293 [TBL] [Abstract][Full Text] [Related]
14. Vaccines for visceral leishmaniasis: A review. Jain K; Jain NK J Immunol Methods; 2015 Jul; 422():1-12. PubMed ID: 25858230 [TBL] [Abstract][Full Text] [Related]
15. Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis. Oliveira-Freitas E; Casas CP; Borja-Cabrera GP; Santos FN; Nico D; Souza LO; Tinoco LW; da Silva BP; Palatnik M; Parente JP; Palatnik-de-Sousa CB Vaccine; 2006 May; 24(18):3909-20. PubMed ID: 16556475 [TBL] [Abstract][Full Text] [Related]
16. Leishmune vaccine: the newest tool for prevention and control of canine visceral leishmaniosis and its potential as a transmission-blocking vaccine. Dantas-Torres F Vet Parasitol; 2006 Oct; 141(1-2):1-8. PubMed ID: 16750885 [TBL] [Abstract][Full Text] [Related]
17. Nucleoside Hydrolase NH 36: A Vital Enzyme for the Palatnik-de-Sousa CB Front Immunol; 2019; 10():813. PubMed ID: 31040850 [TBL] [Abstract][Full Text] [Related]
18. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial. Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339 [TBL] [Abstract][Full Text] [Related]
19. Immunotherapy with the saponin enriched-Leishmune vaccine versus immunochemotherapy in dogs with natural canine visceral leishmaniasis. Borja-Cabrera GP; Santos FN; Santos FB; Trivellato FA; Kawasaki JK; Costa AC; Castro T; Nogueira FS; Moreira MA; Luvizotto MC; Palatnik M; Palatnik-de-Sousa CB Vaccine; 2010 Jan; 28(3):597-603. PubMed ID: 19800443 [TBL] [Abstract][Full Text] [Related]
20. A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amaranto, RN). da Silva VO; Borja-Cabrera GP; Correia Pontes NN; de Souza EP; Luz KG; Palatnik M; Palatnik de Sousa CB Vaccine; 2000 Dec; 19(9-10):1082-92. PubMed ID: 11137242 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]